Overview

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of steady-state concentrations of lazertinib on the single-dose pharmacokinetics (PK) of probe substrates (midazolam, rosuvastatin, and metformin) in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Lazertinib
Metformin
Midazolam
Rosuvastatin Calcium